Cost-Effectiveness of Abatacept, Tocilizumab and TNF-inhibitors Compared With Rituximab as Second-Line Biologic Drug in Rheumatoid Arthritis
PLoS ONE - United States
doi 10.1371/journal.pone.0220142
Full Text
Open PDFAbstract
Available in full text
Categories
Date
July 24, 2019
Authors
Publisher
Public Library of Science (PLoS)